In vivo studies on the binding of heparin and its fractions with platelet factor 4.
PF4 has a half-life in plasma of less than 3 minutes, and its rapid clearance appears to be a function of binding to the vascular endothelium. Once bound to the endothelium, PF4 can be released by heparin in a time-dependent manner; recovery is greater the sooner heparin is administered following PF4 infusion. This heparin-induced release of PF4 can be abolished if the heparin is first complexed with hexadimethrine bromide. Likewise, this heparin-induced release of PF4 is dependent upon the type of heparin used; low molecular weight heparin fractions and fragments do not cause the PF4 rebound seen with intact heparin. Thus, it would appear that low molecular weight forms of heparin are advantageous in that their in vivo administration would not be mediated by such platelet modulators as PF4.
Walz
D A
DA
Hung
G L
GL
D000818:Animals; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D002633:Chemotaxis; D002845:Chromatography; D005174:Factor XII / Q000037:antagonists & inhibitors; D015956:Factor XIIa; D006025:Glycosaminoglycans / Q000378:metabolism; D006493:Heparin / Q000378:metabolism* / Q000494:pharmacology; D006494:Heparin Antagonists; D006801:Humans; D007457:Iodine Radioisotopes; D007553:Isotope Labeling; D008657:Metabolic Clearance Rate / Q000187:drug effects; D003012:Microbial Collagenase / Q000037:antagonists & inhibitors; D008970:Molecular Weight; D010446:Peptide Fragments / Q000037:antagonists & inhibitors; D010978:Platelet Factor 4 / Q000302:isolation & purification / Q000502:physiology*; D011863:Radioimmunoassay; D013329:Structure-Activity Relationship; D014018:Tissue Distribution; D014316:Tritium
D006025:Glycosaminoglycans; D006494:Heparin Antagonists; D007457:Iodine Radioisotopes; D010446:Peptide Fragments; D014316:Tritium; D010978:Platelet Factor 4; D005174:Factor XII; D006493:Heparin; D015956:Factor XIIa; D003012:Microbial Collagenase